Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) - A Phase 2 Multi-centre Trial

NCT06923826 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT06923826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06923826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) - A Phase 2 Multi-centre Trial
Lead sponsor
National University Hospital, Singapore
Phase
Phase 2
Overall status
Recruiting
Start date
April 15, 2025
Completion date
April 30, 2030
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

salivary gland cancer, thyroid cancer